With a robust clinical trial programme, AbbVie is committed to cutting-edge research to drive developments in inflammatory bowel disease (IBD), like ulcerative colitis and Crohn’s disease.

By innovating, learning and adapting, AbbVie aspires to minimise the burden of IBD and make a positive long-term impact on the lives of people with IBD.

For more information on AbbVie in gastroenterology, visit www.abbvie.co.uk.